HC Wainwright Reaffirms Buy Rating for Tenaya Therapeutics (NASDAQ:TNYA)

HC Wainwright reiterated their buy rating on shares of Tenaya Therapeutics (NASDAQ:TNYA) in a report published on Monday, Benzinga reports. HC Wainwright currently has a $18.00 price target on the stock.

Other equities analysts also recently issued research reports about the stock. Chardan Capital reissued a buy rating and issued a $20.00 target price on shares of Tenaya Therapeutics in a research note on Thursday, March 21st. William Blair assumed coverage on shares of Tenaya Therapeutics in a research note on Monday, June 10th. They set an outperform rating on the stock. Finally, Canaccord Genuity Group dropped their price target on shares of Tenaya Therapeutics from $18.00 to $16.00 and set a buy rating on the stock in a research note on Thursday, May 16th. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of Buy and a consensus target price of $15.00.

Tenaya Therapeutics Trading Up 2.3 %

Shares of TNYA stock opened at $3.07 on Monday. The company’s fifty day simple moving average is $3.76 and its 200-day simple moving average is $4.32. Tenaya Therapeutics has a 52 week low of $1.66 and a 52 week high of $7.01. The company has a market cap of $241.06 million, a PE ratio of -1.87 and a beta of 2.42.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Tuesday, May 14th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.03. Equities research analysts expect that Tenaya Therapeutics will post -1.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in TNYA. Redwood Wealth Management Group LLC grew its holdings in Tenaya Therapeutics by 38.0% during the 4th quarter. Redwood Wealth Management Group LLC now owns 16,350 shares of the company’s stock worth $53,000 after acquiring an additional 4,500 shares in the last quarter. SG Americas Securities LLC grew its holdings in Tenaya Therapeutics by 20.0% during the 4th quarter. SG Americas Securities LLC now owns 25,337 shares of the company’s stock worth $82,000 after acquiring an additional 4,224 shares in the last quarter. Bailard Inc. acquired a new position in Tenaya Therapeutics during the 4th quarter worth $107,000. NEOS Investment Management LLC acquired a new position in Tenaya Therapeutics during the 4th quarter worth $201,000. Finally, HighPoint Advisor Group LLC acquired a new position in Tenaya Therapeutics during the 4th quarter worth $228,000. 90.54% of the stock is owned by institutional investors and hedge funds.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.